Mark A Lemmon

List of Publications by Year in Descending Order

156 papers	22,607 citations	76 h-index	150 g-index
163 ext. papers	24,672 ext. citations	14.5 avg, IF	7.21 L-index

#	Paper	IF	Citations
156	Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias.. *Nature*, **2022**,	50.4	4
155	Dynamics of protein kinases and pseudokinases by HDX-MS.. *Methods in Enzymology*, **2022**, 667, 303-338	1.7	0
154	Looking lively: emerging principles of pseudokinase signaling.. *Trends in Biochemical Sciences*, **2022**,	10.3	1
153	Structural basis for ligand reception by anaplastic lymphoma kinase. *Nature*, **2021**, 600, 148-152	50.4	5
152	ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes. *Cell Reports*, **2021**, 37, 109834	10.6	6
151	Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	1
150	Phosphatidylserine binding directly regulates TIM-3 function. *Biochemical Journal*, **2021**, 478, 3331-3349	3.8	3
149	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. *Cancer Research*, **2021**, 81, 1627-1632	10.1	7
148	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. *Molecular Cell*, **2020**, 79, 390-405.e7	17.6	30
147	Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB. *Biochemical Journal*, **2020**, 477, 4053-4070	3.8	1
146	Drug Sensitivity and Allele-specificity of First-line Osimertinib Resistance EGFR Mutations. *FASEB Journal*, **2020**, 34, 1-1	0.9	
145	Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics. *Science Signaling*, **2020**, 13,	8.8	14
144	Insulin and epidermal growth factor receptor family members share parallel activation mechanisms. *Protein Science*, **2020**, 29, 1331-1344	6.3	18
143	Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations. *Cancer Research*, **2020**, 80, 2017-2030	10.1	27
142	Non-acylated Wnts Can Promote Signaling. *Cell Reports*, **2019**, 26, 875-883.e5	10.6	16
141	The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma. *Clinical Cancer Research*, **2019**, 25, 6382-6391	12.9	21
140	Computational algorithms for in silico profiling of activating mutations in cancer. *Cellular and Molecular Life Sciences*, **2019**, 76, 2663-2679	10.3	7

139	Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. *Molecular Cancer Therapeutics*, **2019**, 18, 2124-2134	6.1	5
138	Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. *Structure*, **2018**, 26, 270-281.e4	5.2	4
137	Structures of □klotho reveal a ❑ip code❑like mechanism for endocrine FGF signalling. *Nature*, **2018**, 553, 501-505	50.4	118
136	Smoothening out the patches. *Science*, **2018**, 362, 26-27	33.3	3
135	Flipping ATP to AMPlify Kinase Functions. *Cell*, **2018**, 175, 641-642	56.2	3
134	Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. *Structure*, **2018**, 26, 1137-1143.e3	5.2	9
133	Dimerization of Tie2 mediated by its membrane-proximal FNIII domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 4382-4387	11.5	20
132	Molecular determinants of KA1 domain-mediated autoinhibition and phospholipid activation of MARK1 kinase. *Biochemical Journal*, **2017**, 474, 385-398	3.8	16
131	EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics. *Cell*, **2017**, 171, 683-695.e18	56.2	147
130	The Dark Side of Cell Signaling: Positive Roles for Negative Regulators. *Cell*, **2016**, 164, 1172-1184	56.2	72
129	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. *Cancer Discovery*, **2016**, 6, 96-107	24.4	111
128	Deletion Mutations Keep Kinase Inhibitors in the Loop. *Cancer Cell*, **2016**, 29, 423-425	24.3	2
127	Overcoming resistance to HER2 inhibitors through state-specific kinase binding. *Nature Chemical Biology*, **2016**, 12, 923-930	11.7	21
126	Ligand regulation of a constitutively dimeric EGF receptor. *Nature Communications*, **2015**, 6, 7380	17.4	26
125	EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. *Molecular Genetics & Genomic Medicine*, **2015**, 3, 452-8	2.3	8
124	Comparison of Saccharomyces cerevisiae F-BAR domain structures reveals a conserved inositol phosphate binding site. *Structure*, **2015**, 23, 352-63	5.2	32
123	ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. *Cancer Cell*, **2014**, 26, 682-94	24.3	236
122	Putting together structures of epidermal growth factor receptors. *Current Opinion in Structural Biology*, **2014**, 29, 95-101	8.1	37

121	TIPE3 is the transfer protein of lipid second messengers that promote cancer. *Cancer Cell*, **2014**, 26, 465-78	24.3	69
120	Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. *Cell Reports*, **2014**, 9, 1306-17	10.6	53
119	The EGFR family: not so prototypical receptor tyrosine kinases. *Cold Spring Harbor Perspectives in Biology*, **2014**, 6, a020768	10.2	246
118	Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E3595-604	11.5	89
117	Receptor tyrosine kinases with intracellular pseudokinase domains. *Biochemical Society Transactions*, **2013**, 41, 1029-36	5.1	54
116	Conditional peripheral membrane proteins: facing up to limited specificity. *Structure*, **2012**, 20, 15-27	5.2	132
115	Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. *Biochemical Journal*, **2012**, 448, 213-20	3.8	65
114	Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. *Oncogene*, **2012**, 31, 4859-67	9.2	47
113	Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. *Biochemical Journal*, **2012**, 448, 417-23	3.8	137
112	Occupy EGFR. *Cancer Discovery*, **2012**, 2, 398-400	24.4	6
111	Protein kinase C regulation: C1 meets C-tail. *Structure*, **2011**, 19, 144-6	5.2	7
110	Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. *Biochemical Journal*, **2011**, 436, 241-51	3.8	26
109	Biochemistry. KSR plays CRAF-ty. *Science*, **2011**, 332, 1043-4	33.3	8
108	Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. *Science Translational Medicine*, **2011**, 3, 108ra114	17.5	175
107	Mutations in or near the transmembrane domain alter PMEL amyloid formation from functional to pathogenic. *PLoS Genetics*, **2011**, 7, e1002286	6	41
106	Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. *EMBO Journal*, **2010**, 29, 3054-67	13	88
105	Pleckstrin Homology (PH) Domains **2010**, 1093-1101		2
104	ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 7692-7	11.5	343

103	Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. *Molecular Cell*, **2010**, 40, 877-92	17.6	160
102	Cell signaling by receptor tyrosine kinases. *Cell*, **2010**, 141, 1117-34	56.2	2994
101	Structural basis for negative cooperativity in growth factor binding to an EGF receptor. *Cell*, **2010**, 142, 568-79	56.2	139
100	Kinase associated-1 domains drive MARK/PAR1 kinases to membrane targets by binding acidic phospholipids. *Cell*, **2010**, 143, 966-77	56.2	126
99	N-terminal domains elicit formation of functional Pmel17 amyloid fibrils. *Journal of Biological Chemistry*, **2009**, 284, 35543-55	5.4	79
98	A possible effector role for the pleckstrin homology (PH) domain of dynamin. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 13359-64	11.5	51
97	Role of Inn1 and its interactions with Hof1 and Cyk3 in promoting cleavage furrow and septum formation in S. cerevisiae. *Journal of Cell Biology*, **2009**, 185, 995-1012	7.3	77
96	Functional selectivity of EGF family peptide growth factors: implications for cancer. *Pharmacology & Therapeutics*, **2009**, 122, 1-8	13.9	171
95	Ligand-induced ErbB receptor dimerization. *Experimental Cell Research*, **2009**, 315, 638-48	4.2	160
94	Live cell imaging with protein domains capable of recognizing phosphatidylinositol 4,5-bisphosphate; a comparative study. *BMC Cell Biology*, **2009**, 10, 67		84
93	ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor. *Nature*, **2009**, 461, 287-91	50.4	67
92	The juxtamembrane region of the EGF receptor functions as an activation domain. *Molecular Cell*, **2009**, 34, 641-51	17.6	229
91	Loss of pleckstrin defines a novel pathway for PKC-mediated exocytosis. *Blood*, **2009**, 113, 3577-84	2.2	40
90	Auto-inhibition of dynamin GTPase activity is regulated by PH domain interactions. *FASEB Journal*, **2009**, 23, 697.3	0.9	
89	Regulation of the epidermal growth factor receptor intracellular domain. *FASEB Journal*, **2009**, 23, 883.2	0.9	
88	Structural basis for EGFR ligand sequestration by Argos. *FASEB Journal*, **2009**, 23, 883.7	0.9	
87	ErbB2/HER2/Neu resembles an autoinhibited invertebrate EGF receptor. *FASEB Journal*, **2009**, 23, 884.3	0.9	
86	Phosphoinositide-mimicking peptide sequences are binding targets for PH domains. *FASEB Journal*, **2009**, 23, 873.7	0.9	

85	Characterization of Novel PtdIns(4,5)P2 Effector Domains. *FASEB Journal*, **2009**, 23, 873.6	0.9	
84	Structural basis for EGFR ligand sequestration by Argos. *Nature*, **2008**, 453, 1271-5	50.4	41
83	Membrane recognition by phospholipid-binding domains. *Nature Reviews Molecular Cell Biology*, **2008**, 9, 99-111	48.7	1130
82	Mechanism of activation and inhibition of the HER4/ErbB4 kinase. *Structure*, **2008**, 16, 460-7	5.2	132
81	Pleckstrin homology (PH) domains and phosphoinositides. *Biochemical Society Symposia*, **2007**, 81-93		163
80	Pleckstrin homology (PH) domains and phosphoinositides. *Biochemical Society Symposia*, **2007**, 74, 81-93		176
79	EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. *Oncogene*, **2007**, 26, 1567-76	9.2	71
78	Ligand-induced structural transitions in ErbB receptor extracellular domains. *Structure*, **2007**, 15, 942-54	5.2	83
77	A new twist in the transmembrane signaling tool-kit. *Cell*, **2007**, 130, 213-5	56.2	11
76	Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions. *Trends in Biochemical Sciences*, **2006**, 31, 52-63	10.3	191
75	Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4. *Molecular and Cellular Biology*, **2006**, 26, 831-42	4.8	77
74	On the nature of low- and high-affinity EGF receptors on living cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5735-40	11.5	78
73	Specificity of the myotubularin family of phosphatidylinositol-3-phosphatase is determined by the PH/GRAM domain. *Journal of Biological Chemistry*, **2006**, 281, 31762-9	5.4	32
72	Argos mutants define an affinity threshold for spitz inhibition in vivo. *Journal of Biological Chemistry*, **2006**, 281, 28993-9001	5.4	4
71	Nuclear signaling by receptor tyrosine kinases: the first robin of spring. *Cell*, **2006**, 127, 45-8	56.2	77
70	Palmitoylation of the EGFR ligand Spitz by Rasp increases Spitz activity by restricting its diffusion. *Developmental Cell*, **2006**, 10, 167-76	10.2	99
69	Determining selectivity of phosphoinositide-binding domains. *Methods*, **2006**, 39, 122-33	4.6	109
68	The Dbs PH domain contributes independently to membrane targeting and regulation of guanine nucleotide-exchange activity. *Biochemical Journal*, **2006**, 400, 563-72	3.8	37

67	Specificity of the Myotubularin Family of Phosphatidylinositol-3-phosphatase Is Determined by the PH/GRAM Domain. *Journal of Biological Chemistry*, **2006**, 281, 31762-31769	5.4	7
66	Pleckstrin homology domains: two halves make a hole?. *Cell*, **2005**, 120, 574-6	56.2	32
65	Computational analysis of EGFR inhibition by Argos. *Developmental Biology*, **2005**, 284, 523-35	3.1	33
64	Membrane activity of the phospholipase C-delta1 pleckstrin homology (PH) domain. *Biochemical Journal*, **2005**, 389, 435-41	3.8	47
63	PH Domains **2005**, 337-363		2
62	Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. *Molecular and Cellular Biology*, **2005**, 25, 7734-42	4.8	216
61	The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 923-8	11.5	86
60	The p21-activated protein kinase-related kinase Cla4 is a coincidence detector of signaling by Cdc42 and phosphatidylinositol 4-phosphate. *Journal of Biological Chemistry*, **2004**, 279, 17101-10	5.4	50
59	Inhibition of nuclear import and cell-cycle progression by mutated forms of the dynamin-like GTPase MxB. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 8957-62	11.5	91
58	A structure-based model for ligand binding and dimerization of EGF receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 929-34	11.5	98
57	Svp1p defines a family of phosphatidylinositol 3,5-bisphosphate effectors. *EMBO Journal*, **2004**, 23, 1922-33	15	269
56	Argos inhibits epidermal growth factor receptor signalling by ligand sequestration. *Nature*, **2004**, 430, 1040-4	50.4	114
55	ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. *FEBS Letters*, **2004** , 569, 332-6	3.8	112
54	Genome-wide analysis of membrane targeting by S. cerevisiae pleckstrin homology domains. *Molecular Cell*, **2004**, 13, 677-88	17.6	280
53	The EGF receptor family as therapeutic targets in breast cancer. *Breast Disease*, **2003**, 18, 33-43	1.6	15
52	Phosphoinositide recognition domains. *Traffic*, **2003**, 4, 201-13	5.7	457
51	Genome-wide analysis of signaling domain function. *Current Opinion in Chemical Biology*, **2003**, 7, 103-9	9.7	14
50	EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. *Molecular Cell*, **2003**, 11, 507-17	17.6	565

49	An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Molecular Cell*, **2003**, 12, 541-52	17.6	693
48	SH2 and PTB domains in tyrosine kinase signaling. *Science Signaling*, **2003**, 2003, RE12	8.8	189
47	Loss of phosphatidylinositol 3-phosphate binding by the C-terminal Tiam-1 pleckstrin homology domain prevents in vivo Rac1 activation without affecting membrane targeting. *Journal of Biological Chemistry*, **2003**, 278, 11457-64	5.4	53
46	Pleckstrin Homology (PH) Domains **2003**, 161-169		
45	Phosphoinositide binding by the pleckstrin homology domains of Ipl and Tih1. *Journal of Biological Chemistry*, **2002**, 277, 49935-44	5.4	39
44	The single transmembrane domains of ErbB receptors self-associate in cell membranes. *Journal of Biological Chemistry*, **2002**, 277, 4704-12	5.4	253
43	Pleckstrin homology domains and the cytoskeleton. *FEBS Letters*, **2002**, 513, 71-6	3.8	196
42	Normalization of nomenclature for peptide motifs as ligands of modular protein domains. *FEBS Letters*, **2002**, 513, 141-4	3.8	99
41	Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. *Biochemical Society Transactions*, **2001**, 29, 377-84	5.1	91
40	Analysis of phosphoinositide binding by pleckstrin homology domain from dynamin. *Methods in Enzymology*, **2001**, 329, 457-68	1.7	9
39	Quantitative analysis of the effect of phosphoinositide interactions on the function of Dbl family proteins. *Journal of Biological Chemistry*, **2001**, 276, 45868-75	5.4	78
38	All phox homology (PX) domains from Saccharomyces cerevisiae specifically recognize phosphatidylinositol 3-phosphate. *Journal of Biological Chemistry*, **2001**, 276, 44179-84	5.4	158
37	Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition. *Journal of Biological Chemistry*, **2001**, 276, 4322-9	5.4	53
36	High-affinity binding of a FYVE domain to phosphatidylinositol 3-phosphate requires intact phospholipid but not FYVE domain oligomerization. *Biochemistry*, **2001**, 40, 8581-7	3.2	72
35	Signal-dependent membrane targeting by pleckstrin homology (PH) domains. *Biochemical Journal*, **2000**, 350, 1	3.8	224
34	Signal-dependent membrane targeting by pleckstrin homology (PH) domains. *Biochemical Journal*, **2000**, 350, 1-18	3.8	588
33	Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. *EMBO Journal*, **2000**, 19, 4632-43	13	103
32	The role of the pleckstrin homology domain in membrane targeting and activation of phospholipase Cbeta(1). *Journal of Biological Chemistry*, **2000**, 275, 14873-81	5.4	56

31	Structural basis for discrimination of 3-phosphoinositides by pleckstrin homology domains. *Molecular Cell*, **2000**, 6, 373-84	17.6	310
30	Dominant-negative inhibition of receptor-mediated endocytosis by a dynamin-1 mutant with a defective pleckstrin homology domain. *Current Biology*, **1999**, 9, 261-4	6.3	106
29	Structural bases for specific phosphoinositide binding by PH domains. *Biochemical Society Transactions*, **1999**, 27, A73-A73	5.1	
28	Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. *EMBO Journal*, **1998**, 17, 5374-87	13	307
27	Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. *EMBO Journal*, **1998**, 17, 414-22	13	448
26	Phosphatidylinositol-4,5-bisphosphate is required for endocytic coated vesicle formation. *Current Biology*, **1998**, 8, 1399-402	6.3	218
25	The pleckstrin homology domains of dynamin isoforms require oligomerization for high affinity phosphoinositide binding. *Journal of Biological Chemistry*, **1998**, 273, 27725-33	5.4	161
24	Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. *Journal of Biological Chemistry*, **1998**, 273, 30497-508	5.4	362
23	Kit receptor dimerization is driven by bivalent binding of stem cell factor. *Journal of Biological Chemistry*, **1997**, 272, 6311-7	5.4	82
22	Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. *Oncogene*, **1997**, 14, 687-96	9.2	70
21	Two EGF molecules contribute additively to stabilization of the EGFR dimer. *EMBO Journal*, **1997**, 16, 281-94	13	271
20	Specific role for the PH domain of dynamin-1 in the regulation of rapid endocytosis in adrenal chromaffin cells. *EMBO Journal*, **1997**, 16, 1565-74	13	70
19	Identification of the binding site for acidic phospholipids on the pH domain of dynamin: implications for stimulation of GTPase activity. *Journal of Molecular Biology*, **1996**, 255, 14-21	6.5	231
18	PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. *Cell*, **1996**, 85, 621-4	56.2	459
17	Ala-insertion scanning mutagenesis of the glycophorin A transmembrane helix: a rapid way to map helix-helix interactions in integral membrane proteins. *Protein Science*, **1996**, 5, 1339-41	6.3	68
16	Thermodynamic studies of SHC phosphotyrosine interaction domain recognition of the NPXpY motif. *Journal of Biological Chemistry*, **1996**, 271, 4770-5	5.4	28
15	Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a reappraisal. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 3199-203	11.5	251
14	Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors?. *Cell*, **1995**, 83, 357-60	56.2	442

13	Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain. *Cell*, **1995**, 83, 1037-46	56.2	557
12	Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 10472-6	11.5	492
11	Solution structure of pleckstrin homology domain of dynamin by heteronuclear NMR spectroscopy. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 816-20	11.5	88
10	Regulation of signal transduction and signal diversity by receptor oligomerization. *Trends in Biochemical Sciences*, **1994**, 19, 459-63	10.3	397
9	A dimerization motif for transmembrane alpha-helices. *Nature Structural Biology*, **1994**, 1, 157-63		278
8	Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. *Cell*, **1994**, 79, 1015-24	56.2	605
7	Crystal structure at 2.2 A resolution of the pleckstrin homology domain from human dynamin. *Cell*, **1994**, 79, 199-209	56.2	260
6	Specificity and promiscuity in membrane helix interactions. *FEBS Letters*, **1994**, 346, 17-20	3.8	47
5	Thermodynamic studies of tyrosyl-phosphopeptide binding to the SH2 domain of p56lck. *Biochemistry*, **1994**, 33, 5070-6	3.2	64
4	Specificity and promiscuity in membrane helix interactions. *Quarterly Reviews of Biophysics*, **1994**, 27, 157-218	7	168
3	Sequence specificity in the dimerization of transmembrane alpha-helices. *Biochemistry*, **1992**, 31, 12719-25	3.2	482
2	The glycophorin A transmembrane domain dimer: sequence-specific propensity for a right-handed supercoil of helices. *Biochemistry*, **1992**, 31, 12726-32	3.2	166
1	Helix-helix interactions inside lipid bilayers. *Current Opinion in Structural Biology*, **1992**, 2, 511-518	8.1	50